76 Participants Needed

Virtual Group Speech Therapy for Head and Neck Cancer

MC
HB
Overseen ByHouda Bahig, MD PhD
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This project aims to study an innovative intervention, the eG2 Intervention, developed by speech-language pathologists at the Centre hospitalier de l'Université de Montréal to improve therapeutic adherence and prevent dysphagia in patients treated with chemoradiotherapy for head and neck cancer. The innovation consists in offering a speech therapy intervention that is 1) virtual, 2) group-based (whereas it is usually individual) and 3) involves a patient partner. This intervention has the potential to improve quality of care, accessibility to services and optimize health care resources.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It is best to consult with the trial coordinators or your healthcare provider for guidance.

What data supports the effectiveness of the treatment Virtual Group Speech Pathology Intervention for head and neck cancer?

The research indicates that speech pathology services, which include interventions like the Virtual Group Speech Pathology Intervention, can help improve speech and swallowing functions in patients after head and neck cancer treatment. This is supported by data showing optimal recovery of these functions at six months post-treatment, suggesting that such interventions can be beneficial.12345

Is virtual group speech therapy safe for head and neck cancer patients?

There is no specific safety data available for virtual group speech therapy in head and neck cancer patients, but general safety concerns for online speech therapy include potential voice strain for therapists, which suggests the need for careful monitoring and prevention strategies.26789

How is the Virtual Group Speech Pathology Intervention different from other treatments for head and neck cancer?

The Virtual Group Speech Pathology Intervention is unique because it uses a group setting to help patients practice and apply new speech techniques in a supportive environment, which may enhance the generalization of skills to everyday communication. Additionally, it is delivered virtually, improving access for patients who may face barriers to in-person therapy.1011121314

Eligibility Criteria

Adults over 18 with head or neck cancer starting chemoradiotherapy for cure can join. They need a radiation dose of at least 60 Grays and must speak French well enough for questionnaires. Those with distant cancer spread, planned total laryngectomy, prior severe swallowing issues, another simultaneous cancer, previous head/neck radiation, or significant cognitive impairments cannot participate.

Inclusion Criteria

My radiation therapy is planned to be 60 Grays or more.
I am 18 or older with head or neck cancer.
I am scheduled for chemoradiotherapy aimed at curing my condition.
See 1 more

Exclusion Criteria

I have had serious swallowing problems checked by a speech therapist.
I have been diagnosed with another cancer at the same time as my current one.
I have had radiation therapy to my head or neck.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Chemoradiotherapy

Participants receive chemoradiotherapy treatment for head and neck cancer

6 weeks

Virtual Group Speech Therapy

Participants engage in a virtual, group-based speech therapy intervention guided by a patient partner

Concurrent with chemoradiotherapy

Follow-up

Participants are monitored for safety and effectiveness after treatment, including evaluation of nasogastric tube placement

6 weeks

Treatment Details

Interventions

  • Virtual Group Speech Pathology Intervention
Trial OverviewThe trial is testing the eG2 Intervention: a virtual group speech therapy guided by a patient partner to prevent swallowing difficulties in patients undergoing chemoradiotherapy for head and neck cancers. It aims to improve care quality and accessibility while optimizing healthcare resources.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: virtual group speech therapy intervention guided by a patient partnerExperimental Treatment1 Intervention

Virtual Group Speech Pathology Intervention is already approved in Canada for the following indications:

🇨🇦
Approved in Canada as eG2 Intervention for:
  • Prevention of dysphagia in patients treated with chemoradiotherapy for head and neck cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Centre hospitalier de l'Université de Montréal (CHUM)

Lead Sponsor

Trials
389
Recruited
143,000+

Université du Québec à Trois-Rivières

Collaborator

Trials
48
Recruited
4,500+

Findings from Research

This study analyzed functional outcomes in 293 head and neck cancer patients treated in Victoria, Australia, providing valuable data on speech, swallowing, and quality of life after treatment.
The findings suggest that optimal recovery of function typically occurs around six months post-treatment, establishing a reference point for future comparisons in similar patient populations.
An evaluation of functional outcomes (speech, swallowing) in patients attending speech pathology after head and neck cancer treatment(s): results and analysis at 12 months post-intervention.Perry, AR., Shaw, MA., Cotton, S.[2006]
The study involved 67 head and neck cancer patients and found that many experienced speech and swallowing problems, which significantly impacted their quality of life and emotional well-being.
Using the OncoQuest computerized monitoring system in an outpatient clinic proved feasible for tracking these issues, highlighting the importance of ongoing assessment in managing patient outcomes.
Computerized monitoring of patient-reported speech and swallowing problems in head and neck cancer patients in clinical practice.Cnossen, IC., de Bree, R., Rinkel, RN., et al.[2021]
In a 3-month pilot clinic involving 218 patients with head and neck cancer, Speech and Language Therapists (SLTs) effectively conducted assessments and treatment planning, demonstrating a safe collaboration with otolaryngologists.
The clinic identified a low cancer diagnostic yield of 5%, but found that higher scores on voice assessments (GRBAS) and patient-reported outcomes (VHI-10) were associated with a greater risk of serious diagnoses, suggesting these measures could help in identifying patients needing further evaluation.
Outcomes of an Advanced Speech and Language Therapist-Led Low-Risk 2-Week Wait Clinic for Suspected Head and Neck Cancer: A UK-Based Pilot Study.Butler, J., Sellstrom, D., Eastwood, N., et al.[2023]

References

An evaluation of functional outcomes (speech, swallowing) in patients attending speech pathology after head and neck cancer treatment(s): results and analysis at 12 months post-intervention. [2006]
Computerized monitoring of patient-reported speech and swallowing problems in head and neck cancer patients in clinical practice. [2021]
Outcomes of an Advanced Speech and Language Therapist-Led Low-Risk 2-Week Wait Clinic for Suspected Head and Neck Cancer: A UK-Based Pilot Study. [2023]
Evaluation of functional outcomes (speech, swallowing and voice) in patients attending speech pathology after head and neck cancer treatment(s): development of a multi-centre database. [2019]
Speech pathology service enhancement for people with head and neck cancer living in rural areas: Using a concept mapping approach to inform service change. [2021]
Muscle Tension Dysphonia: A Sequeale of Chemoradiotherapy in Patients of Head and Neck Cancer. [2023]
Phonogenic Voice Problems among Speech-Language Pathologists in Synchronous Telepractice: An Overview and Recommendations. [2021]
Relating speech and swallow function to dropout in a longitudinal study of head and neck cancer. [2007]
The usefulness of the Electronic Patient Visit Assessment (ePVA)© as a clinical support tool for real-time interventions in head and neck cancer. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Effects of Voice Therapy: A Comparison Between Individual and Group Therapy. [2018]
11.United Statespubmed.ncbi.nlm.nih.gov
Application of telepractice for head and neck cancer management: a review of speech language pathology service models. [2018]
Home-based speech treatment for Parkinson's disease delivered remotely: a case report. [2022]
13.United Statespubmed.ncbi.nlm.nih.gov
Randomized controlled trial of a multisite speech pathology telepractice service providing swallowing and communication intervention to patients with head and neck cancer: Evaluation of service outcomes. [2022]
14.United Statespubmed.ncbi.nlm.nih.gov
Voice Therapy Outcome-A Randomized Clinical Trial Comparing Individual Voice Therapy, Therapy in Group, and Controls Without Therapy. [2021]